Despite receiving a second CRL Henwood indicates that the company would continue to pursue an approval of IV meloxicam with this indication, will request a meeting of FDA, and work with FDA to make a forward path.
Despite receiving a second CRL, Henwood indicated that the company will continue to pursue an approval for IV meloxicam for this indication, will request a meeting with the FDA, and work with the FDA to find a path forward.